Beware of catching a falling k

2023-02-13

Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.

G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":9954633055,"tweetId":"9954633055","gmtCreate":1676300342478,"gmtModify":1676302498607,"author":{"id":3562115684410726,"idStr":"3562115684410726","authorId":3562115684410726,"authorIdStr":"3562115684410726","name":"KingCrab","avatar":"https://static.tigerbbs.com/405b64f3c681fc35136b02e8b5a53c12","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.</p></body></html>","htmlText":"<html><head></head><body><p>Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.</p></body></html>","text":"Beware of catching a falling knife. Although GTHX has fallen dramatically, I wouldn't buy in yet. As a dividend income invester, I would avoid the company as it is not paying dividend. However if the stock were to fall 3 days consecutively, I may trade this counter as a day trader.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9954633055","repostId":2311278989,"repostType":2,"repost":{"id":"2311278989","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1676291924,"share":"https://www.laohu8.com/m/news/2311278989?lang=&edition=full","pubTime":"2023-02-13 20:38","market":"us","language":"en","title":"G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2311278989","media":"Dow Jones","summary":"G1 Therapeutics Inc. said it has decided to discontinue its Phase 3 trial, called Preserve 1, that t","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.</p><p>Shares fell 55% to $3.2 in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058bf0f8b0deeb4381b26c96de767e1e\" tg-width=\"838\" tg-height=\"840\" width=\"100%\" height=\"auto\"/></p><p>The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.</p><p>However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.</p><p>&#34;All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,&#34; G1 Chief Executive Jack Bailey said. &#34;We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.&#34;</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>G1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nG1 Therapeutics to Discontinue Metastatic Colorectal Cancer Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-02-13 20:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.</p><p>Shares fell 55% to $3.2 in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058bf0f8b0deeb4381b26c96de767e1e\" tg-width=\"838\" tg-height=\"840\" width=\"100%\" height=\"auto\"/></p><p>The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.</p><p>However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.</p><p>&#34;All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,&#34; G1 Chief Executive Jack Bailey said. &#34;We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.&#34;</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4539":"次新股","BK4007":"制药","BK4191":"家用电器","TERN":"Terns Pharmaceuticals, Inc.","CRCT":"Cricut, Inc.","GTHX":"G1 Therapeutics Inc.","BK4139":"生物科技"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2311278989","content_text":"G1 Therapeutics Inc. said it has decided to discontinue its Phase 3 trial, called Preserve 1, that tested trilaciclib administered along with triplet therapy with Folfoxiri and bevacizumab in patients with metastatic colorectal cancer.Shares fell 55% to $3.2 in premarket trading.The company said the trial achieved its co-primary endpoints showing clinically meaningful reductions in severe neutropenia during induction, as well as in the average duration of severe neutropenia. Patients treated with trilaciclib also showed a reduction in the rate of chemotherapy-induced diarrhea, the company said.However, early anti-tumor efficacy data favored patients in the placebo arm of the trial, the company said.\"All of us at G1 are disappointed in this surprising outcome for patients with CRC, but we remain committed to the potential of trilaciclib to impact the lives of many cancer patients in other indications,\" G1 Chief Executive Jack Bailey said. \"We are increasingly encouraged by the real-world performance of trilaciclib in patients with extensive stage small cell lung cancer and look forward to upcoming readouts in our other ongoing trials.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":198,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":232,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/9954633055"}